0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Food and Drug Administration |

New Drug for HIV-1 Infection

Bernard A. Schwetz, DVM, PhD
JAMA. 2001;286(21):2660. doi:10.1001/jama.286.21.2660.
Text Size: A A A
Published online

Extract

The FDA has approved tenofovir disoproxil fumarate tablets (Viread, Gilead Sciences Inc, Foster City, Calif) in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread is a prodrug of tenofovir (nucleotide analog), which exhibits activity against HIV reverse transcriptase.

The indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in a controlled study of 24 weeks' duration and in a controlled, dose-ranging study of 48 weeks' duration. Treatment-experienced adults with evidence of HIV-1 viral replication despite ongoing antiretroviral therapy were randomized to receive either Viread or placebo in addition to their stable background regimen of antiretroviral agents. In both studies, the mean baseline CD4 cell count was approximately 410/µL, median baseline plasma HIV RNA was approximately 3500 copies/mL, and mean duration of prior HIV treatment was approximately 5 years.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();